FDA Approves Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria
The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.
Drug Administration Upper Limit Twice Daily Oral With Residual Anemia Despite Anti C Twice Daily Oral Iptacopan Who Are Naive
Source: hcplive.com